Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

GSG. SrinivasanHSHaran Srinivasan SaravananKVKrishna teja Vemulaghat

Discussion

Loading...

Member takes

Overview

Meta-analysis shows MSC infusion reduces graft vs host disease incidence in HSCT patients, suggesting improved outcomes.

Key Points

  • To evaluate the efficacy and safety of mesenchymal stromal cell (MSC) infusion in preventing graft vs host disease (GVHD) post-HSCT.
  • Conducted a systematic review and meta-analysis following PRISMA guidelines.
  • Literature search included PubMed, Scopus, Embase, and Google Scholar up to July 2025.
  • Analyzed randomized controlled trials comparing MSC prophylaxis with standard care for GVHD prevention.
  • MSCs reduced incidence of acute GVHD from 41.17% to 16.47% compared to controls.
  • Severe acute GVHD occurred in 2.35% of MSC patients versus 18.23% in controls.
  • MSC therapy enhanced GVHD-free relapse-free survival to 61.2% compared to 29.4% in controls.

Cite This Study

Srinivasan et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d631https://doi.org/10.1182/blood-2025-7773
View Full Paper
Ask AI
Bookmark
Share